Welcome to Flow Pharma Inc.

Page Loading...

Menu
blob-1
blob-2
Our Biomedicines

FLOVID-20

Targeted T-cell Immunotherapy
A treatment for new COVID-19 patients. Administered by inhaler or injection. Designed to prevent severe COVID-19 disease and cure COVID ‘long-haulers’.


Vaccination by Inhalation or Injection. FLOVID-20 can use inhalation or injection to deliver a preventative and therapeutic immuno-stimulatory biomedicine targeting nucleocapsid epitopes on SARS-CoV-2.

Mutations of COVID-19 are frequent and unpredictable—FLOVID-20 is targeting the virus at places predicted by Flow Pharma scientists to be least likely to mutate. So far, none of the known COVID-19 virus variants have mutations in those locations.

Overview

Current Status

  • PRE-CLINICAL FEASIBILITY
  • MANUFACTURING FOR CLINICAL TESTING
  • PHASE I/II CLINICAL TESTING

Treated primates resisted infection. Control primates developed COVID pneumonia.

How Does Our Therapy Work?


What is COVID-19 and SARS-CoV-2?

Novel Coronavirus SARS-CoV-2

COVID-19 is the disease caused by Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

This scanning electron microscope image shows SARS-CoV-2 (round gold objects) emerging from the surface of cells cultured in the lab. The virus shown was isolated from a patient in the U.S. Image captured and colorized at NIAID’s Rocky Mountain Laboratories (RML) in Hamilton, Montana. Credit: NIAID

Read More.


Want to learn more about the science behind the solution?

View Resources